Treatment of mild to moderate plaque psoriasis with calcitriol ointment applied with or without a dosing device

European Journal of Inflammation

Volumn 5, Issue 2, 2007, Pages 89-95

  Vena, G A ^b   Cassano, N ^b   Alessandrini, G ^a   Fai, D ^a   Gabellone, M ^a   Ligori, P ^a   Malvindi, C ^a   Mancino, A ^a   Pelle, S ^a   Rinaldi, F ^a   Sodo, M R ^a  

^a Collegio Salentino di Dermatologia ^*  (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Calcitriol; Dosing device; Plaque psoriasis; Topical treatmen; Vitamin D3 analogue

Indexed keywords

CALCITRIOL; LACTIC ACID; NUTRAPLUS FORTE; UNCLASSIFIED DRUG; UREA;

ACCURACY; ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; OUTCOME ASSESSMENT; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SKIN PRURITUS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34548072896     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X0700500205     Document Type: Article

References (24)

1. Milde P. 1991. Vitamin D und die Haut: neue Aspekte und Perspektiven. Hautarzt 42:671.
2. Nezbedova P. and J. Brtko. 2004. 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action. Endocr. Regul. 38:29.
3. Milde P., U. Hauser, T. Simon, G. Mall, V. Ernst, M.R. Haussler, P. Frosch and E.W. Rauterberg. 1991. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Invest. Dermatol. 97:230.
4. Reichrath J., S.M. Muller, A. Kerber, H.P. Baum and F.A. Bahmer. 1997. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J. Am. Acad. Dermatol. 36:19.
5. Reichrath J., A. Perez, S.M. Muller, T.C. Chen, A. Kerber, F.A. Bahmer and M.F. Holick. 1997. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm. Venereol. 77:268.
6. Lemire J. 2000. 1,25-Dihydroxyvitamin D3-a hormone with immuno-modulatory properties. Z. Rheumatol. 59(S)1:24.
7. May E., K. Asadullah and U. Zugel. 2004. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr. Drug Targets Inflamm. Allergy 3:377.
8. Franssen M.E., G.J. de Jongh, P.E. van Erp and P.C. van de Kerkhof. 2004. A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations. Acta Derm. Venereol. 84:195.
9. Langner A., H. Verjans, V. Stapor, M. Mol and M. Fraczykowska. 1993. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. Br. J. Dermatol. 128:566.
10. Hutchinson P.E., R. Marks and J. White. 2000. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 201:139.
11. Kowalzick L. 2001. Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. Br. J. Dermatol. 144(S):21.
12. Langner A., W. Stapor and M. Ambroziak. 2001. Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. Br. J. Dermatol. 144(S):11.
13. Ortonne J.P., P. Humbert, J.F. Nicolas, N. Tsankov, S.D. Tonev, A. Janin, J. Czernielewski, M. Lahfa and L. Dubertret. 2003. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br. J. Dermatol. 148:326.
14. Camarasa J.M., J.P. Ortonne and L. Dubertret. 2003. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J. Dermatolog. Treat. 14:8.
15. Savary J., J.P. Ortonne and S. Aractingi. 2005. The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments. J. Eur. Acad. Dermatol. Venereol. 19(S):14.
16. Langner A., P. Ashton, P.C. Van De Kerkhof and H. Verjans. 1996. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br. J. Dermatol. 135:385.
17. Bourke J.F., S.J. Iqbal and P.E. Hutchinson. 1997. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 micrograms/g) and calcipotriol (50 micrograms/ g) in the treatment of chronic plaque psoriasis vulgaris. Acta Derm. Venereol. 77:228.
18. Queille-Roussel C., L. Duteil, A. Parneix-Spake, S. Arsonnaud and E. Rizova. 2001. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur. J. Dermatol. 11:219.
19. Rizova E. and M. Corroller. 2001. Topical calcitriol - studies on local tolerance and systemic safety. Br. J. Dermatol. 144(S):3.
20. Gerritsen M.J., P.C. Van De Kerkhof and A. Langner. 2001. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br. J. Dermatol. 144(S):17.
21. Barker J.N., J. Berth-Jones, R. Groves, A.D. Omerod, E. Rizova and C.E. Griffiths. 2003. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J. Dermatolog. Treat. 14:14.
22. Long C.C., C.M. Mills and A.Y. Finlay. 1998. A practical guide to topical therapy in children. Br. J. Dermatol. 138:293.
23. Lynfield Y.L. and B.A. Schecter. 1984. Choosing and using a vehicle. J. Am. Acad. Dermatol. 10:56.
24. Vena G.A., N. Cassano, C.P. Agnusdei, M. Bellini, S. Calabretta, S. Centofanti, G. Cervadoro, C. Coviello, S. Curia, S. Dattola et al. 2005. Treatment of psoriasis vulgaris with calcipotriol/betamethasone diproprionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur. J. Inflamm. 3:37.